Full Text | PDF

Share on facebook Share on tweeters Share on linkedin Share on googleplus

Int J Med Sci 2023; 20(2):262-266. doi:10.7150/ijms.81381 This issue Cite

Review

Mechanism of CD38 via NAD+ in the Development of Non-alcoholic Fatty Liver Disease

Min Dong1, Shuo Wang2, Zuowei Pei3,4✉

1. Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
2. Department of Internal Medicine, The Affiliated Zhong Shan Hospital of Dalian University, Dalian, China.
3. Department of Cardiology, Central Hospital of Dalian University of Technology, Dalian, China.
4. Faculty of Medicine, Dalian University of Technology, Dalian, China.

✉ Corresponding author: Zuowei Pei, Department of Cardiology, Central Hospital of Dalian University of Technology, No.826 Xinan Road, 116033, Dalian, Telephone number: +86-0411-84412001, E-mail: pzw_dlcom.

Citation:
Dong M, Wang S, Pei Z. Mechanism of CD38 via NAD+ in the Development of Non-alcoholic Fatty Liver Disease. Int J Med Sci 2023; 20(2):262-266. doi:10.7150/ijms.81381. https://www.medsci.org/v20p0262.htm
Other styles

File import instruction

Abstract

Graphic abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease globally, and it can proceed to cirrhosis and hepatocellular carcinoma, as well as cardiovascular disease, chronic renal disease, and other complications, resulting in a massive economic burden. At the moment, nicotinamide adenine dinucleotide (NAD+) is thought to be a possible treatment target for NAFLD, besides Cluster of differentiation 38(CD38) is the primary NAD+ degrading enzyme in mammals and may play a role in the pathophysiology of NAFLD. For example, CD38 regulates Sirtuin 1 activity and hence affects inflammatory responses. CD38 inhibitors enhance glucose intolerance and insulin resistance in mice and lipid accumulation in the liver is greatly decreased in CD38-deficient mice. This review describes the role of CD38 in the development of NAFLD in terms of Macrophage-1, insulin resistance, and abnormal lipid accumulation in order to offer recommendations for future NAFLD pharmacological trials.

Keywords: Non-alcoholic fatty liver disease, CD38, NAD+, Macrophage-1 Insulin resistance, Lipid accumulation.

Citation styles

APA
Dong, M., Wang, S., Pei, Z. (2023). Mechanism of CD38 via NAD+ in the Development of Non-alcoholic Fatty Liver Disease. International Journal of Medical Sciences, 20(2), 262-266. https://doi.org/10.7150/ijms.81381.

ACS
Dong, M.; Wang, S.; Pei, Z. Mechanism of CD38 via NAD+ in the Development of Non-alcoholic Fatty Liver Disease. Int. J. Med. Sci. 2023, 20 (2), 262-266. DOI: 10.7150/ijms.81381.

NLM
Dong M, Wang S, Pei Z. Mechanism of CD38 via NAD+ in the Development of Non-alcoholic Fatty Liver Disease. Int J Med Sci 2023; 20(2):262-266. doi:10.7150/ijms.81381. https://www.medsci.org/v20p0262.htm

CSE
Dong M, Wang S, Pei Z. 2023. Mechanism of CD38 via NAD+ in the Development of Non-alcoholic Fatty Liver Disease. Int J Med Sci. 20(2):262-266.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use